Year Published
- 2008 (0)
- (-) Remove 2009 filter 2009
- 2010 (0)
- 2011 (0)
- 2012 (0)
- 2013 (0)
- 2014 (0)
- (-) Remove 2015 filter 2015
- 2016 (2) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (0)
- 2020 (0)
- 2021 (0)
Research Topics
Populations
- Countries/Governments (1) Apply Countries/Governments filter
- Rural Populations (0)
- Smallholder Farmers (0)
- Women (0)
Types of Research
- Data Analysis (1) Apply Data Analysis filter
- (-) Remove Literature Review filter Literature Review
- Portfolio Review (0)
- Research Brief (0)
Geography
- East Africa Region and Selected Countries (0)
- (-) Remove Global filter Global
- South Asia Region and Selected Countries (1) Apply South Asia Region and Selected Countries filter
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- Sub-Saharan Africa (3) Apply Sub-Saharan Africa filter
- West Africa Region and Selected Countries (0)
Dataset
- ASTI (0)
- FAOSTAT (0)
- Farmer First (0)
- LSMS & LSMS-ISA (0)
- Other Datasets (0)
Current search
- (-) Remove Research & Development filter Research & Development
- (-) Remove 2015 filter 2015
- (-) Remove 2017 filter 2017
- (-) Remove Southern Africa Region and Selected Countries filter Southern Africa Region and Selected Countries
- (-) Remove Information & Mobile Technology filter Information & Mobile Technology
- (-) Remove 2009 filter 2009
- (-) Remove Global filter Global
- (-) Remove Literature Review filter Literature Review
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
A “new wave” of digital credit products has entered the digital financial services (DFS) market in recent years. These products differ from traditional credit by offering loans to borrowers that can be applied for, approved, and disbursed remotely (often without any brick-and-mortar infrastructure), automatically (generally minimizing or eliminating person-to-person interaction), and instantly (often in less than 72 hours). Digital credit also increasingly considers creditworthiness by using alternative (nontraditional) data—ranging from mobile phone activity to utility payments and social media data—potentially allowing for loans to populations previously unable to access bank credit. Two EPAR reports review the characteristics of digital credit offerings in India, Kenya, Nigeria, Tanzania, and Uganda, and regulations specific to digital credit in Africa and Asia.